



11 September 2025

Sydney, Australia

Notice of Change of Interests of Substantial Securityholder ("Notice")

Nyrada Inc (ASX: NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, advises further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depository Interests ("CDIs"), a Notice of Change of Interests of Substantial Holder in relation to Nyrada. Details of the initial interest in CDIs ("Relevant Interests") are as follows:

Name of Substantial Holder: Mr Mark Azzi

Date of change in the interests of the Substantial Holder: 10 September 2025

Previous and present voting power of Substantial Holder (through CHES Depository Nominees Pty Ltd):

Previous notice		Present notice	
Number of CDIs	Voting power	Number of CDIs	Voting Power
35,618,250	14.92%	38,052,227	15.93%

Present Relevant Interests:

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power (1)
Mr Mark Azzi	Mr Mark Azzi	37,452,227	15.68%
Mr Mark Azzi	Mr Mark Azzi	600,000	0.25%

(1) Based on 238,895,370 CDIs on issue on issue as outlined in Appendix 2A released to ASX on 09 September 2025.

For personal use only



Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

– ENDS –

About Nyrada Inc

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. James Bonnar, CEO on behalf of the Board.

Investor & Corporate Enquiries:

Dimitri Burshtein

T: 02 9498 3390

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@atomicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.